

8/D

Docket No. JAB-1669

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Raymond Antoine Stokbroekx, et al.
Serial No. : 09/998,975
Filed : November 19, 2001
Title : Angiogenesis Inhibiting 5-Substituted-1,2,4-Thiadiazolyl Derivatives
Art Unit : 1624
Examiner : Truong, Tamthom Ngo

I hereby certify that this correspondence is being sent by facsimile to (703) 308-4556
to: Commissioner of Patents, Washington, D.C. 20231 on 03/20/2003.

03/20/2003

(Date of Deposit)

Alana G. Kriegsman, Esq.

(Name of applicant, assignee, or Registered Representative)



(Signature)

03/20/2003

(Date of Signature)

*Enter
3-28-03
RCP*

Honorable Commissioner of Patents
Washington, D.C. 20231

SUPPLEMENTAL AMENDMENT AFTER FINAL
37 C.F.R. 1.116

Dear Sir:

In response to the Final Office Action mailed December 20, 2002, Applicants respectfully request consideration and entry of the following Supplemental amendment, which Applicants believe put the case in condition for allowance. This Amendment is submitted in the Revised Amendment Format that the Office is considering adopting via a revision to 37 CFR 1.121 (as detailed in the pre-OG Notice entitled "Amendments in Revised Format Now Permitted").¹

¹ See USPTO Website at <http://www.uspto.gov/web/offices/pac/dapp/opla/preognotice/revamdtpac.htm>